101
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

, , , , , , , , , & show all
Pages 2519-2530 | Published online: 01 Oct 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Benjamin Kearns, Katy Cooper, Anna Cantrell & Chloe Thomas. (2021) Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. Neuropsychiatric Disease and Treatment 17, pages 125-137.
Read now

Articles from other publishers (7)

Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari & Paola Rocca. (2023) Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines 11:3, pages 921.
Crossref
George T. Kannarkat, Stanley N. Caroff & James F. Morley. (2022) Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. Tremor and Other Hyperkinetic Movements 12:1.
Crossref
Lauren Stummer, Marija Markovic & Megan Maroney. (2020) Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer’s disease. Neurodegenerative Disease Management 10:4, pages 205-217.
Crossref
Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma & Nakao Iwata. (2020) Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology 237:5, pages 1459-1470.
Crossref
Yusaku Yoshimura, Hiroma Shimizu, Rieko Yamashita, Kenji Washida, Toshihiko Takeda & Shozo Aoki. (2020) Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology 35:2, pages 98-104.
Crossref
Akimasa Sanagawa, Nao Shiraishi, Fumino Sekiguchi, Tatsuo Akechi & Kazunori Kimura. (2019) Successful Use of Brexpiprazole for Parkinson's Disease Psychosis Without Adverse Effects. Journal of Clinical Psychopharmacology 39:6, pages 685-687.
Crossref
Miloslav Kopeček. (2019) Brexpiprazole. Praktické lékárenství 15:E-verze 1/19.
Crossref